DiaMedica Therapeutics, Inc.

  • Home
  • Our Focus
    • Overview
    • Literature & Publications
  • Pipeline
    • Overview
    • Acute Ischemic Stroke
    • Cardio-Renal Disease
  • Clinical Trials
    • Overview
    • Acute Ischemic Stroke
  • ReMEDy2
    • Overview
    • About ReMEDy2
    • Stroke Disease
    • For Physicians
    • Trial Locations
  • About DiaMedica
    • Overview
    • Leadership
    • Careers
    • Contact
  • Investors Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Data
    • Analyst Coverage
    • Financial Reports & SEC Filings
    • Governance
    • Resources

Press Releases

Investors Relations

Investors Relations

  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Data
    • Nasdaq Quote
    • Charts
    • Historical Data
  • Analyst Coverage
  • Financial Reports & SEC Filings
    • SEC Filings
    • Annual Reports
    • Tax Information (PFIC)
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • Investor Contact
    • FAQ
    • Share Consolidation Instructions
    • Email Alerts
Sep 12, 2023 8:13am EDT

DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer

Sep 06, 2023 8:35am EDT

DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference

Aug 14, 2023 4:13pm EDT

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results

Aug 08, 2023 8:32am EDT

DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023

Jul 18, 2023 8:30am EDT

DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference

Jun 26, 2023 8:30am EDT

DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement

Jun 21, 2023 8:39am EDT

DiaMedica Therapeutics Announces $37.5 Million Private Placement

Jun 21, 2023 8:15am EDT

DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

May 30, 2023 8:29am EDT

DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

May 15, 2023 4:28pm EDT

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …13
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2023 DiaMedica Therapeutics, Inc. All Rights Reserved.
Twitter LinkedIn
Privacy Policy Disclaimer Sitemap